Atomwise vs Healx

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Atomwise employs 75 people, while Healx has 1-50 employees.

Atomwise has raised more in total funding at $219M, compared to Healx's $47M — a gap of $172M. Combined, the two companies have completed 5 known funding rounds.

Healx holds the higher Awaira Score at 55/100, compared to Atomwise's 53/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 2-point gap that reflects meaningful differences in scale or traction.

Atomwise was founded by Abraham Heifets in 2012. Healx was founded by Tim Guilliams in 2014. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised.

Atomwise was founded first in 2012, giving it 2 years of additional market experience. Healx was founded later in 2014. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Atomwise has approximately 75 employees, while Healx has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Atomwise and Healx are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.